Clinical trial starts for cervical cancer drug
A Kyoto University group says it has started a clinical trial of a substance that could help prevent the development of cervical cancer by stopping the growth of a virus known as a cause.
The group of researchers from the university’s medical department told a news conference on Thursday that they aim to win government approval for the use of the substance as a new cancer drug.
The substance in question was developed 15 years ago in a research that was unrelated to cervical cancer.
Cervical cancer is mostly caused by infections with human papilloma virus. The group has found that the substance they have developed can prevent this type of cancer by stopping the growth of the virus at an early stage.
The clinical trial started in April, targeting 22 patients. They are infected with the virus and have already been exhibiting symptoms that, if left untreated, could develop into cervical cancer.
The patients are being given the new drug over a period of two weeks. Their conditions will be monitored for over a year to check the drug’s safety and effectiveness.
Professor Masatoshi Hagiwara of Kyoto University is leading the clinical trial.
He said that currently, surgery is the only option available to patients found with virus-induced conditions that could lead to cervical cancer. He said his group is aiming to develop a drug that could stop the development of pre-cancer conditions into a full-fledged cancer. He said the group’s ultimate goal is to make sure no women die of cervical cancer.